



DIGITAL ACCESS TO SCHOLARSHIP AT HARVARD

Structural basis for pure antagonism of integrin $\alpha 3$ by a high affinity form of fibronectin

The Harvard community has made this article openly available.
[Please share](#) how this access benefits you. Your story matters.

Citation	Van Agthoven, Johannes F., Jian-Ping Xiong, José Luis Alonso, Xianliang Rui, Brian D. Adair, Simon L. Goodman, and M. Amin Arnaout. 2014. "Structural basis for pure antagonism of integrin $\alpha 3$ by a high affinity form of fibronectin." <i>Nature structural & molecular biology</i> 21 (4): 383-388. doi:10.1038/nsmb.2797. http://dx.doi.org/10.1038/nsmb.2797 .
Published Version	doi:10.1038/nsmb.2797
Accessed	February 17, 2015 3:50:35 AM EST
Citable Link	http://nrs.harvard.edu/urn-3:HUL.InstRepos:13347584
Terms of Use	This article was downloaded from Harvard University's DASH repository, and is made available under the terms and conditions applicable to Other Posted Material, as set forth at http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-use#LAA

(Article begins on next page)

Published in final edited form as:

Nat Struct Mol Biol. 2014 April ; 21(4): 383–388. doi:10.1038/nsmb.2797.

Structural basis for pure antagonism of integrin α V β 3 by a high affinity form of fibronectin

Johannes F. Van Agthoven^{1,*}, Jian-Ping Xiong^{1,*}, José Luis Alonso², Xianliang Rui², Brian D. Adair¹, Simon L. Goodman³, and M. Amin Arnaout^{1,2}

¹Structural Biology Program, Massachusetts General Hospital, 149 13th Street, Charlestown, MA 02129

²Leukocyte Biology & Inflammation Program, Department of Medicine, Massachusetts General Hospital, 149 13th Street, Charlestown, MA 02129

³Harvard Medical School, Global Research and Early Development, Translational Innovation platform, Oncology, Merck KGaA, Darmstadt 64271, Germany

Abstract

Integrins are important therapeutic targets. However, current RGD-based anti-integrin drugs are also partial agonists, inducing conformational changes that trigger potentially fatal immune reactions and paradoxical cell adhesion. Here we describe the first crystal structure of α V β 3 bound to a physiologic ligand: the 10th type III RGD-domain of wild-type fibronectin (wtFN10), or to a high affinity mutant (hFN10) that acts as a pure antagonist. Comparison of these structures revealed a central π - π interaction between Trp1496 in the RGD-containing loop of hFN10 and Tyr122 of the β 3-subunit that blocked conformational changes triggered by wtFN10, and trapped hFN10-bound α V β 3 in an inactive conformation. Removing the Trp1496 or Tyr122 side-chains, or reorienting Trp1496 away from Tyr122, converted hFN10 into a partial agonist. The findings offer new insights on the mechanism of integrin activation and a basis for design of RGD-based pure antagonists.

Introduction

Integrins are α/β heterodimeric cell adhesion receptors which consist of a bilobular head and two legs that span the plasma membrane^{1–2}. Integrins are unusual receptors, as they normally exist on the cell surface in an inactive state, unable to engage physiologic ligand. This is critical for integrin biology as it allows, for example, patrolling blood platelets and

Correspondence and requests for materials should be addressed to M.A.A. (arnaout1@mgh.harvard.edu).

*Equal contributors.

Accession codes

The coordinates and structure factors of α V β 3-hFN10, α V β 3-wtFN10 and α V β 3-hFN10/B have been deposited in the Protein Data Bank under accession codes 4MMZ, 4MMX, and 4MMY, respectively.

Author Contributions

M.A.A. conceived and designed experiments. J.V.A., J-P.X. and S.L.G. made and purified proteins. JVA and JPX performed the crystallographic studies. J.L.A., X.R., J.V.A., M.A.A. and B.D.A. performed the biophysical, biochemical and cell-based assays. M.A.A., J.V.A., J-P.X. and J.L.A. interpreted data. M.A.A. wrote the manuscript with the assistance of S.L.G. and J-P.X.

Competing Financial Interests The authors declare no competing financial interests.

immune cells to circulate with minimal aggregation or interaction with vessel walls. Physiologic stimuli (e.g. chemokines), acting through the short integrin cytoplasmic tails, induce allosteric changes in the ectodomain required for extracellular ligand binding (“inside-out” activation)³. Binding of physiologic ligands induces “outside-in” signaling by initiating additional structural rearrangements in the ectodomain⁴, which induce conformational epitopes (*Ligand-induced binding sites*, LIBS) such as those recognized by monoclonal antibodies AP5 (ref. 5), LIBS-1 and LIBS-6 (ref. 6). These ligand-induced structural rearrangements trigger cell spreading⁷ via connections between the integrin cytoplasmic tails and filamentous actin⁸. Disruption of these processes contributes to the pathogenesis of many diseases^{9–11}.

Despite the clinical efficacy of cyclic RGD-like molecules that target platelet integrin α IIB β 3 in preventing thrombosis, parenteral ligand-mimetic antagonists of α IIB β 3, such as the cyclic heptapeptide eptifibatide, can induce severe thrombocytopenia—a major life-threatening complication—in up to 2% of treated patients¹². In addition, during oral therapy of acute coronary syndromes, RGD-mimetic drugs paradoxically induced thrombosis and mortality, contributing to the failure of clinical trials⁹.

Crystal structures of integrin ectodomains in complex with small RGD-based peptidomimetics^{13,14} show the RGD motif binding the integrin head: Arg contacts the Propeller domain of the α -subunit, and Asp binds the β A domain of the β -subunit at a *metal-ion-dependent-adhesion-site* (MIDAS) via Mg^{2+} (or Mn^{2+}). Two regulatory Ca^{2+} cations at the *ligand-associated metal binding site* (LIMBS or synergistic, SyMBS) and at *adjacent to MIDAS* (ADMIDAS), flank the MIDAS metal ion¹³. The Ca^{2+} at ADMIDAS links the N- and C-terminal helices, stabilizing the inactive conformation¹⁵. Binding of ligand-mimetic compounds is mechanically coupled to tertiary changes in the β A domain involving inward movement of the N-terminal α 1 helix towards the MIDAS, forcing reorganization of the C-terminal F-strand/ α 7 loop, a one-turn displacement of helix α 7 and a Hybrid domain swing-out (reviewed in ref. 3). These movements may persist after dissociation of these compounds, contributing to immune thrombocytopenia¹⁶, and facilitating physiologic ligand binding to a “primed” integrin, an effect that may have contributed to the increased mortality in patients treated with RGD-mimetic compounds targeting platelet α IIB β 3 (ref. 17). RGD-containing α V β 3 antagonists (e.g. cilengitide¹⁸) can paradoxically stimulate model tumor growth and angiogenesis¹⁹, possibly through partial agonism of α V β 3. A recent attempt to address the issue of partial agonism utilized a non-RGD small molecule that acts competitively to destabilize Mg^{2+} at MIDAS in integrin α IIB β 3, an effect reversed at higher Mg^{2+} concentrations²⁰. To date however no RGD-based pure antagonists have been identified.

In the modular matrix protein fibronectin (FN), the wild-type 10 kDa 10th type III domain (wtFN10) is necessary and sufficient for binding to α V β 3 (ref. 21). Here we report the first crystal structure of an integrin α V β 3 ectodomain bound to a physiologically relevant ligand: the FN10 domain. We show that in contrast wtFN10, a high affinity form of this ligand (hFN10) acts as a pure antagonist for α V β 3. To clarify the structural basis for this activity, we also determined the crystal structure of the hFN10– α V β 3. Comparisons of the structures

revealed a novel mechanism underlying pure antagonism by an RGD containing ligand that suggests a path to the generation of RGD-based drugs that can act as pure antagonists.

RESULTS

Binding of hFN10 to resting and activated cellular $\alpha V\beta 3$

We compared the integrin binding properties of wtFN10 to those of a high affinity form of FN10 (hFN10) that was selected for specific $\alpha V\beta 3$ binding from a FN10 phage display library, where five residues N- and C-terminal to the RGD motif were randomized²². In hFN10, the sequence ¹⁴⁹²PRGDWNEG replaces ¹⁴⁹²GRGDSPAS of wtFN10. Interestingly, RGDWN is also the core sequence in the disintegrin barbourin (on which the drug eptifibatid was based²³), excepting an R-to-K substitution, which enhances specificity of barbourin for platelet $\alpha IIb\beta 3$ over $\alpha V\beta 3$ (ref. 14).

The binding of fluoresceinated fluid-phase wtFN10 to stably expressed wild-type $\alpha V\beta 3$ in K562 cells (K562- $\alpha V\beta 3$) was a low background in physiological concentrations of Ca^{2+} and Mg^{2+} (Ca^{2+} - Mg^{2+} , 1mM each) (Fig. 1a), as expected, since soluble physiologic ligands do not bind to the inactive integrin in physiological Ca^{2+} / Mg^{2+} containing buffers. Binding of soluble wtFN10 was increased 10-fold in presence of the integrin activator Mn^{2+} , a mimic of inside-out activation²⁴ (Fig. 1a), or 6-fold by an N339S mutation in the βA domain, which constitutively activates $\alpha V\beta 3$ both *in vitro* and *in vivo*²⁵(Fig. 1b). By contrast, strong binding, 6-fold background, of soluble fluoresceinated hFN10 to K562- $\alpha V\beta 3$ occurred in Ca^{2+} - Mg^{2+} and was increased a further ~1.5 fold by Mn^{2+} (Fig. 1a). Binding of hFN10 was similar both on wild type (WT) $\alpha V\beta 3$ and to $\alpha V\beta 3$ (N339S), each transiently-expressed on HEK293T cells (Fig. 1b).

Effects hFN10 binding to $\alpha V\beta 3$

The integrin activator Mn^{2+} induces expression of LIBS mAbs AP5 (ref. 5), LIBS-1 and LIBS-2 (ref. 6), each recognizing distinct epitopes in the $\beta 3$ -subunit. mAb AP5 recognizes an N-terminal sequence in the PSI (plexin-semaphorin-integrin) domain⁵, mAb LIBS-1 recognizes a different epitope from AP5, and LIBS-6 binds the C-terminal membrane proximal βTD domain. LIBS expression is further increased upon binding of physiologic ligand⁵.

As expected, Mn^{2+} -driven binding of wtFN10 to K562- $\alpha V\beta 3$ increased expression of LIBS mAbs AP5, LIBS-1 and LIBS-6 above that induced by Mn^{2+} alone (Fig. 1c). In contrast, binding of hFN10 not only did not induce LIBS expression, but also significantly decreased LIBS expression induced by Mn^{2+} alone (Fig. 1c). We saw this effect whether $\alpha V\beta 3$ was expressed artificially (on K562 cells) or constitutively (on melanoma M21 cells). And while binding of wtFN10 to the constitutively active $\alpha V\beta 3$ (N339S) integrin, increased AP5 epitope expression by ~2-fold, binding of hFN10 did not (Fig. 1d).

It is known that Mn^{2+} or the binding of soluble RGD-based ligands induces conformational changes in $\alpha V\beta 3$ ectodomain, detected by changes in the hydrodynamic radius of the ectodomain^{4,26,27}. We therefore examined the effects of binding of hFN10 to the $\alpha V\beta 3$ ectodomain in solution by comparing the hydrodynamic radii of $\alpha V\beta 3$ -hFN10 and $\alpha V\beta 3$ -

wtFN10 complexes by molecular sieve chromatography^{4,27}. Preformed α V β 3-hFN10 and α V β 3-wtFN10 complexes (Supplementary Fig. 1a) were chromatographed on a molecular sieve column equilibrated in the relevant metal ion-containing buffer, and Stokes' radii were derived as described previously⁴. The complexes displayed dramatically different profiles (Fig. 1e and Supplementary Fig. 2b): wtFN10 increased the Stokes' radius (R_s) of α V β 3 in Mn^{2+} (6.6nm), compared to the integrin size in Mn^{2+} alone (R_s 6.3 nm), as expected. However, hFN10 had little effect on the R_s of α V β 3 in Mn^{2+} (6.3 nm) or in Ca^{2+}/Mg^{2+} (6.0 nm vs. 5.9 nm in the absence of hFN10).

Cell spreading is a reporter of ligand-induced outside-in signaling²⁸. To determine the effect of hFN10 on spreading, we compared spreading of α V β 3-expressing cells on surfaces coated with native full-length FN (positive control) (Fig. 1f), wtFN10 (Fig. 1f, g) or hFN10 (Fig. 1f, h). After 2h, approximately 90% of attached cells spread on native FN and 60% on wtFN10. In contrast, less than 20% of attached cells spread on hFN10. Cell attachment under all conditions was eliminated when assays were carried out in presence of the function-blocking LM609 mAb against α V β 3 (not shown).

Crystal structures of α V β 3-wtFN10 and α V β 3-hFN10 complexes

To clarify the structural basis for the inhibitory effects of bound hFN10 on conformational changes and function of α V β 3, we soaked the macromolecular ligands hFN10 or wtFN10 into crystals of the α V β 3 ectodomain⁴ in 2mM $MnCl_2$, and determined the crystal structures of the resulting α V β 3-hFN10 and α V β 3-wtFN10 complexes (Fig. 2a, b, Supplementary Fig. 2, and Table 1). hFN10- or wtFN10-bound α V β 3 remained genuflected, with each ligand bound at the integrin head, as expected. However, orientation of FN10 relative to the β A domain differed dramatically between the two complexes, with a $\sim 60^\circ$ rotation around the RGD-loop (Fig. 2c). *Fo-Fc* omit maps (generated after omitting the FN10 ligand), revealed clear positive densities (Supplementary Fig. 2c, d), reflecting stable engagement of the integrin head by ligand. The omit maps showed clear density for the complete hFN10 domain, but for only $\sim 60\%$ of wtFN10, that facing the integrin, with the wtFN10 segment farthest away from the integrin showing minimal density, consistent with its low affinity and the likely flexibility of this region in the crystal.

The RGD motif of each ligand bound the α V β 3 head in an identical manner (Fig. 3a, b), and as shown previously for the RGD-containing pentapeptide, cilengitide¹³: RGD inserted into the crevice between the Propeller and β A domains, and contacted both. The α V β 3-wtFN10 interface was modestly larger than the α V β 3-cilengitide interface, mainly due to contacts wtFN10 made with the glycan at the propeller residue Asn266, which included H-bonds with mannose 2271 (MAN2271) (Fig. 3a). An N266Q substitution in cellular α V β 3 did not impair heterodimer formation (as judged by binding of the heterodimer-specific mAb LM609, not shown) but reduced adhesion of HEK293T cells expressing the constitutively active mutant integrin α V(N266Q) β 3(N339S) to immobilized full-length FN by 56% vs. adhesion mediated by α V β 3(N339S) in Ca^{2+} - Mg^{2+} buffer ($p=0.003$, $n=3$ independent experiments)(Supplementary Fig.3a).

One structural feature which coincided with the higher affinity of hFN10 compared to wtFN10 was the more extensive α V β 3-hFN10 interface, largely due to the additional and

distinct contacts hFN10 made mainly with the MIDAS face and with the specificity-determining loop (SDL) of the β A domain (Fig. 3b). These contributed to the different orientation of hFN10 on α V β 3 and the coordination patterns of the Mn^{2+} ion at MIDAS and ADMIDAS (Fig. 3b). In contrast to the α V β 3-wtFN10 interface, hFN10 made no contacts with the Propeller glycan at Asn266. At the center of the hFN10- β A contacts was a π - π edge-to-face interaction of the mutant Trp1496 in hFN10 with Tyr122 in the α 1 helix of β A (Fig. 3b). Tyr122 also H-bonded to Glu1462 of hFN10, which also formed a salt bridge with Lys125 of β A. The hydroxyl oxygen of hFN10-Tyr1446 also coordinated the Mn^{2+} at ADMIDAS via a water molecule. The outcome of these interactions was that the tertiary changes induced by the physiologic ligand wtFN10 (i.e. inward movement of the N-terminal α 1 helix towards MIDAS, and reorganization of the C-terminal F-strand/ α 7 loop) were absent in the hFN10-bound β A domain (Fig. 3c). Indeed, the structure of hFN10-bound β A was superimposable on that of the unliganded β A domain (Fig. 3c). That is to say: the hFN10-bound β A domain assumed the same conformation as the unliganded β A domain. The hFN10-bound α V β 3 structure also displayed other features of an inactive state⁴ that were absent from the α V β 3-wtFN10 structure. These included electrostatic interactions between the two subunits at the β -genu (Supplementary Fig. 3b), and between the β A and β TD within the β 3 subunit (Supplementary Fig. 3c). Together these findings suggested that when bound to hFN10, α V β 3 was at or close to an inactive ground state that would not transduce outside-in signals, despite ligand occupancy.

The Trp1496-Tyr122 π - π interaction was crucial for blocking conformational changes induced by binding of ligand as shown in mutational studies. Removing Trp1496 side chain, through Trp1496 to Ser substitution (hFN10W/S) converted hFN10 into a partial agonist that could induce binding of the LIBS mAb AP5 to cellular α V β 3 (Fig. 3d)²⁹. Similarly, when the Tyr122 side chain was removed, through a Tyr to Ala mutation in the β A domain, hFN10-bound α V β 3(Y122A) now also expressed LIBS (Fig. 3d).

Reorienting Trp1496 converts hFN10 into a partial agonist

The core RGDWN sequence in hFN10 matches that in barbourin, a partial agonist of α IIb β 3. Yet, superposition of the RGD-containing loops in hFN10, barbourin (pdb id 1q7j) and the drug eptifibatide (pdb id 2vdn¹⁴) revealed drastically different orientations of the Trp side-chain in hFN10 compared to that in barbourin/eptifibatide. In contrast to Trp1496 side-chain in hFN10, this points inwards towards the center of the RGD loop in barbourin/eptifibatide structures, away from the critical Tyr122 side chain of the β A domain (Fig. 4a). And binding of either barbourin or eptifibatide induces expression of AP5 LIBS¹⁴. We mutated three loop residues flanking the RGDWN sequence in hFN10 (TPRGDWNE) so as to match the barbourin sequence (IAKGDWND), and purified this hFN10/B domain. The crystal structure of the α V β 3-hFN10/B complex (Supplementary Fig. 4) showed that the main-chain and side-chain structure of the RGD-loop residues IARGDWNE were clear in the *Fo-Fc omit* map (Supplementary Fig. 4), but the rest of hFN10/B domain was not visible, likely reflecting flexibility at the new N- and C-termini of the RGD-containing loop. It was clear however, that the main-chain structure of this loop changed to position the C α and C β of Trp1496 in the α V β 3-hFN10/B complex as in barbourin or eptifibatide (Fig. 4b), with the Trp1496 side-chain in hFN10/B repositioned so that it no longer faces the Tyr122 side-chain

of βA (Fig. 4c). This reorientation was associated with the unhindered inward movement of Tyr122 in the $\alpha 1$ helix, as in the eptifibatide-bound integrin¹⁴. The binding of hFN10/B to cellular $\alpha V\beta 3$ consistently induced expression of mAb AP5 LIBS similar to that induced by wtFN10 (Fig. 4d and Supplementary Fig. 5).

DISCUSSION

In this study we report the crystal structures of integrin $\alpha V\beta 3$ in complex with an RGD-bearing domain of the physiologically relevant macromolecular ligand fibronectin (wtFN10), and with a high affinity form of this domain of fibronectin (hFN10) carrying substitutions adjacent to the RGD sequence. Our major finding is that hFN10 unexpectedly acts as a pure antagonist of $\alpha V\beta 3$, based on biochemical, biophysical and cell-biological data, and lacks the partial agonism of the native ligands also observed in other RGD-like ligands. The structural basis for antagonism was revealed by the crystal structures of $\alpha V\beta 3$ -hFN10 and $\alpha V\beta 3$ -hFN10.

When it bound to cellular $\alpha V\beta 3$, hFN10, unlike wtFN10, did not induce activation-specific conformational LIBS mAb epitopes in the integrin N- and C-terminal domains. And it reduced LIBS expression induced both by the activating cation Mn^{2+} and by constitutive (mutational) activation of $\alpha V\beta 3$. Second, hFN10 bound to, but did not dramatically alter the hydrodynamic behavior of the soluble $\alpha V\beta 3$ ectodomain, unlike wtFN10 or cyclic RGD-based peptides⁴. Third, cell spreading on immobilized hFN10 was significantly reduced compared with wtFN10 or native FN. Cell spreading reports outside-in signaling by ligand-occupied integrins²⁸.

The $\alpha V\beta 3$ -hFN10 structure defines for the first time the interface an integrin makes with a macromolecular physiologic ligand. Interestingly, this interface was surprisingly modest even relative to $\alpha V\beta 3$ -cilengitide interface¹³ and was distinguished by contacts with the glycan at Asn266 of the α -subunit Propeller domain. These contacts significantly contributed to the adhesion function of cellular $\alpha V\beta 3$. The glycan at Asn266 is conserved in the fibronectin receptor $\alpha 5\beta 1$ (ref. 30), and mutation of the equivalent residue in $\alpha 5$ (N275Q) impaired $\alpha 5\beta 1$ -mediated cell adhesion³¹, suggesting that the glycan contact may also be in the $\alpha 5\beta 1$ /FN interface. This interface is also expected to be more robust than the $\alpha V\beta 3$ /FN interface, due to an interaction of FN-type III domain 9- with the α -subunit Propeller, an interaction that is not used by $\alpha V\beta 3$ (ref. 21). This may explain the greater susceptibility of the smaller $\alpha V\beta 3$ -FN interface to force-induced binding/unbinding events, which may make it more suitable than the more extensive $\alpha 5\beta 1$ -FN interface for mediating dynamic outside-in signal transduction³². Thus, the wtFN10- $\alpha V\beta 3$ structure provides a molecular explanation for the distinct cellular responses seen when different integrins bind to the same ligand-domain.

Structure of the $\alpha V\beta 3$ -hFN10 complex identified a basis for the unexpected action of hFN10 as a pure antagonist despite its prototypical RGD motif. Structural and mutational studies support a critical role for the novel Trp1496-Tyr122 $\pi - \pi$ interaction in “freezing” the integrin in an inactive conformation. First, removing the Trp1496 side chain from hFN10 resulted in a domain that acted as wtFN10, as reported by LIBS expression. LIBS were also

induced by hFN10 binding to cellular $\alpha V\beta 3$ lacking the Tyr122 side chain. Second, changing the orientation of the Trp1496 side chain in hFN10 such that it no longer faced Tyr122 (as seen in the structure of $\alpha V\beta 3$ -hFN10/B complex) also lead to induction of LIBS when cellular $\alpha V\beta 3$ bound hFN10/B. These data strongly argue that blocking the inward movement of the $\alpha 1$ helix towards MIDAS is sufficient to halt associated tertiary changes in the βA domain leading to outside-in signaling. Thus, altering side-chain orientation of Trp1496 by design or selection of its local environment can dramatically affect the tertiary or quaternary changes induced by binding of RGD-based ligands. This could perhaps be replicated. For example: in a cyclized form of the RGD-containing loop of hFN10; by changing orientation of Trp side chain in eptifibatide; or by replacing D-Phe with D-Trp in a modified cilengitide. The critical βA -Tyr122 is also conserved in $\alpha 5\beta 1$ (ref. 30) and $\beta 2$ integrins³³, which like $\alpha V\beta 3$ are drug targets³⁴. Our surprising results thus clearly suggest a path to a structure-based drug design of a new generation of ligand-mimetic integrin inhibitors that can act as pure antagonists.

Online Methods

Reagents and antibodies

Restriction and modification enzymes were obtained from New England Biolabs Inc. (Beverly, MA). Cell culture reagents were purchased from Invitrogen Corp (San Diego, CA) or Fisher Scientific (Hampton, NH). Human plasma fibronectin was obtained from Sigma-Aldrich (St Louis, MO). The non-inhibitory mouse monoclonal antibody (mAb) AP3 (American Type Culture Collection, ATCC) detects the $\beta 3$ -subunit in all conformations. Mouse mAb AP5, kindly provided by T.J. Kunicki (Blood Centre, Madison, WI), detects residues 1–6 in the PSI domain of the $\beta 3$ -subunit only in high-affinity/ligand-bound states. Mouse mAbs LIBS-1 and LIBS-6 to the human $\beta 3$ -subunit⁶ were kindly provided by Dr. M. Ginsberg (University of California, San Diego). LIBS-1 binds a neoepitope distinct from that of AP5, and LIBS-6 binds the βTD (residues 602–690) (ref. 5). The Fab fragment of AP5 was prepared by papain digestion followed by anion exchange and size-exclusion chromatography. The function-blocking and heterodimer-specific mAb LM609 to $\alpha V\beta 3$ (ref. 35) was from Millipore (Danvers, MA) and APC-labeled goat anti-mouse Fc-specific antibody was from Jackson ImmunoResearch (West Grove, PA).

Plasmids, mutagenesis, protein expression and purification

Human $\alpha V\beta 3$ ectodomain was expressed in insect cells and purified as described³⁶. The activating N339S mutation in the $\beta 3$ subunit was generated as described³⁷. Expression plasmids encoding wild-type human N-terminally His-tagged FN10 (S1417-T1509) were generated by PCR from a plasmid containing human FN7-10 kindly provided by H.P. Erickson (Duke University Medical Center, Durham, NC)³⁸. Plasmid encoding His-tagged high affinity FN10 (hFN10) was PCR-generated by replacing the cDNA encoding the loop sequence ¹⁴⁹²GRGDSPAS in wtFN10 with ¹⁴⁹²PRGDWNEG. RGD-loop substitutions W1496S and TPRGDWNE to IARGDWND (substituted residues underlined) in hFN10 to produce hFN10W/S and hFN10/B, respectively, were generated using PCR-based mutagenesis with the Quick-change kit (Agilent Technologies), cloned into bacterial expression plasmid pET11a and verified by DNA sequencing. The double mutation N266/Q

(in α V Propeller) plus N339S (in β A domain), and the Y122A mutation were generated by PCR in pcDNA3 expression plasmids and confirmed by DNA sequencing. FN10 forms were expressed in bacteria and purified by affinity chromatography on nickel columns followed by gel filtration. Thrombin-cleaved FN10 was further purified by gel filtration. Protein purity was confirmed by SDS PAGE.

Cell lines, cell culture and transfection

The human erythroleukemia cell line K562 stably expressing recombinant α V β 3 (K562- α V β 3)⁴ and the human melanoma cell line M21, which constitutively expresses α V β 3, have been previously described³⁹. Cells were maintained in Iscove's modified Dulbecco's medium plus G418 (0.5–1.0 mg/ml) (K562- α V β 3) or RPMI1640 (M21), supplemented with 10% fetal calf serum, 2mM L-glutamine, penicillin and streptomycin. HEK293T (ATCC) cells cultured in Dulbecco modified Eagle's medium supplemented with 10% fetal calf serum, 2mM L-glutamine, 1 mM sodium pyruvate, penicillin and streptomycin, were transiently co-transfected with pcDNA3 plasmids encoding full-length WT α V β 3, α V β 3(Y122A), α V β 3(N339S), or α V(N266Q) β 3(N339S) using Lipofectamine 2000 reagent (Invitrogen) according to the manufacturer's protocol.

Fluorescent labeling of FN10 and mAbs

FN10, and mAbs AP5 (Fab) and AP3 (IgG) were labeled respectively with N-hydroxy succinimidyl esters of Fluor 488 (Alexa488) and Alexa647, (Invitrogen) according to the manufacturer's instructions. Excess dye was removed using Centri-Spin size-exclusion microcentrifuge columns (Princeton Separations, Adelphia, NJ). The final FN10, AP5 and AP3 concentrations and dye to protein molar ratios (F/P) were determined spectrophotometrically, giving F/P molar ratios of 1.2 (for FN10) and 3 (for AP5 and AP3).

Ligand binding and flow cytometry

In cellular and biochemical assays where calcium, magnesium or manganese ions were used, they were each at final concentrations of 1 mM. Cells stably (K562) or transiently (HEK293T) expressing WT or mutant forms of α V β 3 were harvested by incubating in 10 mM EDTA in PBS (5 min; 25°C), followed by washing three times in Hepes-buffered saline (20 mM Hepes, 150 mM NaCl, pH 7.4) containing bovine serum albumin (BSA) (0.1% w/v; washing buffer, WB). 1×10^6 cells were suspended in 100 μ l WB containing CaCl₂ plus MgCl₂ or MnCl₂ (10 min; 37°C), and incubated first with Alexa488-labeled wt- or hFN10 (each at 3–10 μ g/ml) (30 min; 25°C) in the dark, then with Alexa647-conjugated AP3 (10 μ g/ml) for an additional 30 min on ice. Cells were washed in the respective metal ion-containing buffer, resuspended, fixed in 4% paraformaldehyde and analyzed using FACSCalibur or BD-LSRII flow cytometers (BD Biosciences). Binding of soluble FN10 to α V β 3⁺ cells was expressed as mean fluorescence intensity (MFI), as determined using FlowJo software. Binding of soluble FN10 to HEK293T was normalized by dividing its MFI by the MFI of Alexa647-conjugated AP3 to the same cells and multiplying by 100. Mean and SD from independent experiments were calculated, and compared using Student's t test.

LIBS epitope expression

K562- α V β 3 cells, transiently transfected HEK293T or α V β 3⁺ M21 cells (0.5×10^6 in $100 \mu\text{l}$ WB) were incubated in the absence or presence of unlabeled soluble FN10 ($5 \mu\text{g}$) in $\text{Ca}^{2+}/\text{Mg}^{2+}$ or in Mn^{2+} (30 min; at 25°C). Alexa647-labeled AP5 Fab, unlabeled anti-LIBS-1 (each to $10 \mu\text{g}/\text{ml}$) or LIBS-6 ascites (to 1:50 dilution) were added, and the cells were incubated for an additional 30 min before washing. Alexa647-labeled AP3 was used with HEK293T cells in a separate set of tubes for normalization. APC-labeled goat anti-mouse Fc-specific antibody was added to anti-LIBS-1- or anti-LIBS-6-bound M21 cells for an additional 30 min at 4°C . Cells were then washed, resuspended, fixed in 4% paraformaldehyde and analyzed by flow cytometry. LIBS epitope expression was measured and expressed as MFI (in case of K562- α V β 3 or M21 cells) and normalized (in case of HEK293T cells) as above.

Hydrodynamic shift assays

α V β 3 ectodomain was incubated alone or with FN10 (at 2:1 FN10/integrin molar ratio) in 145 mM NaCl and 25 mM Tris-HCl, pH 7.4 (TBS) containing Ca^{2+} , $\text{Ca}^{2+}/\text{Mg}^{2+}$ or Mn^{2+} (20°C ; 1.5 h). Aliquots were then taken and chromatographed at room temperature on a precalibrated Superdex S-200 GL column equilibrated in buffer having the same metal ion composition used during the incubation, and Stokes radii were derived as described previously⁴. The elution profiles resolved by molecular sieve chromatography were monitored in-line by UV adsorption at 280 nm. Unliganded \pm FN10-treated α V β 3 species were resolved as single discrete symmetrical peaks. Excess FN10 served as an internal standard. Identity of resolved peaks was formally confirmed by SDS-PAGE.

Cell adhesion assays

wtFN10, hFN10 or full-length FN (each at a $100 \mu\text{g}/\text{ml}$ in PBS) was adsorbed to demarcated areas in Maxisorp Nunc Omni Tray plates (Sigma-Aldrich, St Louis, MO) overnight at 25°C . The various FN-coated surfaces were washed with PBS, and blocked with bovine serum albumin (5% w/v in PBS; 1h; 25°C). K562- α V β 3 cells (5×10^4) were added (in TBS; 1mM Mn^{2+}), in the absence or presence of LM609 mAb ($10 \mu\text{g}/\text{ml}$, added 15 min prior to plating). Cells were incubated (2h; 37°C), washed three times in warm TBS and fixed with 4% formaldehyde (in PBS; 25°C ; 10 min). Images were captured using an inverted phase microscope (Zeiss Axiovert 40CFL) fitted with a powershot G12 Cannon Camera. ImageJ 1.48a software (National Institutes of Health, USA) was used to quantify cell spreading of 300–400 random selected cells. Spread cells were clearly distinguishable from round, refringent non-spread cells. Representative phase contrast images were collected using Zeiss Axiovert 35 inverted microscope using a CCD camera and Spot software (Diagnostics Instruments). Adhesion of transiently transfected HEK293T expressing equivalent amounts of α V β 3(N339S) or α V(N266Q) β 3(N339S) was done by adding cells (3×10^4) in TBS containing Ca^{2+} - Mg^{2+} and 0.1% BSA (w/v) to FN-coated surfaces (45min; 25°C). Non-adherent cells were removed by washing and adherent cells were fixed (2% paraformaldehyde; 30 min; 25°C), stained (0.1% Crystal Violet; 30 min; 25°C), washed with water, air dried and then solubilized (1% SDS). Relative cell attachment was estimated

by absorbance of the lysates at 540 nm measured using a SpectraMax M2E Microplate reader (Molecular Devices, Sunnyvale, CA).

Crystallography, structure determination, and refinement

α V β 3 ectodomain was crystallized at 4°C by vapor diffusion using the hanging drop method as previously described⁴. hFN10, wtFN10 or hFN10/B (at 1.5 mM) were soaked into α V β 3 crystals in the crystallization well solution containing 2 mM Mn²⁺ for 2–3 weeks. Crystals were harvested in 12% PEG 3500 (polyethylene glycol, molecular weight 3500), in 100 mM sodium acetate, pH 4.5, 800 mM NaCl plus 2 mM Mn²⁺ and FN10 (at 1.5 mM), cryoprotected by addition of glycerol in 2% increments up to 24% final concentration, and then flash-frozen in liquid nitrogen. Diffraction data from cryocooled crystals were collected on the ID19 beamline fitted with a CCD detector at the APS Facility (Chicago, IL). Data were indexed, integrated and scaled with HKL2000 program⁴⁰ for α V β 3-hFN10, α V β 3-hFN10B, and with iMosflm⁴¹ for α V β 3-wtFN10, using the same R_{free} set imported from pdb id 3ije structure factors. Phases were determined by molecular replacement using PHASER⁴², with structures of unliganded α V β 3 ectodomain (pdb 3ije) and FN10 domain (pdb 1fnf) used as search models. The resulting models were refined with 1.8.4 version of Phenix 11⁴³ using simulated annealing, TLS, positional and individual temperature-factor refinement, and default restraints. Several cycles of refinement and model building using Coot⁴⁴ were applied to refine the complex structures of α V β 3-hFN10, α V β 3-wtFN10 and α V β 3-hFN10/B (Table 1), with automatic optimization of X-ray and stereochemistry/ADP, and additional Ramachandran restraints in last cycles. Ramachandran statistics were as follows: α V β 3-hFN10 structure, 89% in most favored regions, 10.47% in additional allowed regions and 0.53% outliers; α V β 3-wtFN10 structure, 89% in most favored regions, 10.18% in additional allowed regions and 0.82% outliers; α V β 3-hFN10/B structure, 91% in most favored regions, 0.56% in additional allowed regions and 0.56% outliers. σ A weighted *F_o-F_c* omit maps were generated by removing the FN10 ligand from the final complex models using phenix.maps. All structural illustrations were prepared with the Chimera software⁴⁵.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgments

We thank Dr. Harold .P. Erickson (Duke University) for providing the FN7-10 plasmid, Dr. Thomas J. Kunicki (The Scripps Research Institute) for access to AP5 antibody, Dr. Mark Ginsberg (UC San Diego) for providing LIBS-1 and LIBS-6 mAbs, Dr. Gregory A. Petsko (Brandeis University) for helpful discussions and Zhiping Ding and Dirk Mueller-Pompalla for expert technical assistance. This work was supported by grants DK48549, DK096334 and DK007540 (M.A.A.) from NIDDK, National Institutes of Health.

References

1. Hynes RO. Integrins: bidirectional, allosteric signaling machines. *Cell*. 2002; 110:673–687. [PubMed: 12297042]
2. Xiong JP, et al. Crystal structure of the extracellular segment of integrin alpha Vbeta3. *Science*. 2001; 294:339–345. [PubMed: 11546839]
3. Arnaout MA, Goodman SL, Xiong JP. Structure and mechanics of integrin-based cell adhesion. *Curr Opin Cell Biol*. 2007; 19:495–507. [PubMed: 17928215]

4. Xiong JP, et al. Crystal structure of the complete integrin alphaVbeta3 ectodomain plus an alpha/beta transmembrane fragment. *The Journal of cell biology*. 2009; 186:589–600. [PubMed: 19704023]
5. Honda S, et al. Topography of ligand-induced binding sites, including a novel cation-sensitive epitope (AP5) at the amino terminus, of the human integrin beta 3 subunit. *The Journal of biological chemistry*. 1995; 270:11947–11954. [PubMed: 7538128]
6. Frelinger AL 3rd, Du XP, Plow EF, Ginsberg MH. Monoclonal antibodies to ligand-occupied conformers of integrin alpha IIb beta 3 (glycoprotein IIb-IIIa) alter receptor affinity, specificity, and function. *The Journal of biological chemistry*. 1991; 266:17106–17111. [PubMed: 1894607]
7. Raborn J, Wang W, Luo BH. Regulation of integrin alphaIIbbeta3 ligand binding and signaling by the metal ion binding sites in the beta I domain. *Biochemistry*. 2011; 50:2084–2091. [PubMed: 21309594]
8. Friedland JC, Lee MH, Boettiger D. Mechanically activated integrin switch controls alpha5beta1 function. *Science*. 2009; 323:642–644. [PubMed: 19179533]
9. Cox D, Brennan M, Moran N. Integrins as therapeutic targets: lessons and opportunities. *Nature reviews. Drug discovery*. 2010; 9:804–820.
10. Gerber EE, et al. Integrin-modulating therapy prevents fibrosis and autoimmunity in mouse models of scleroderma. *Nature*. 2013; 503:126–130. [PubMed: 24107997]
11. Maile LA, et al. A monoclonal antibody against alphaVbeta3 integrin inhibits development of atherosclerotic lesions in diabetic pigs. *Science translational medicine*. 2010; 2:18ra11.
12. Aster RH, Curtis BR, McFarland JG, Bougie DW. Drug-induced immune thrombocytopenia: pathogenesis, diagnosis, and management. *Journal of thrombosis and haemostasis : JTH*. 2009; 7:911–918. [PubMed: 19344362]
13. Xiong JP, et al. Crystal structure of the extracellular segment of integrin alpha Vbeta3 in complex with an Arg-Gly-Asp ligand. *Science*. 2002; 296:151–155. [PubMed: 11884718]
14. Xiao T, Takagi J, Collier BS, Wang JH, Springer TA. Structural basis for allostery in integrins and binding to fibrinogen-mimetic therapeutics. *Nature*. 2004; 432:59–67. [PubMed: 15378069]
15. Mould AP, Barton SJ, Askari JA, Craig SE, Humphries MJ. Role of ADMIDAS Cation-binding Site in Ligand Recognition by Integrin {alpha}5{beta}1. *The Journal of biological chemistry*. 2003; 278:51622–51629. [PubMed: 14532288]
16. Gao C, et al. Eptifibatide-induced thrombocytopenia and thrombosis in humans require FcgammaRIIa and the integrin beta3 cytoplasmic domain. *The Journal of clinical investigation*. 2009; 119:504–511. [PubMed: 19197137]
17. Bassler N, et al. A mechanistic model for paradoxical platelet activation by ligand-mimetic alphaIIb beta3 (GPIIb/IIIa) antagonists. *Arteriosclerosis, thrombosis, and vascular biology*. 2007; 27:e9–e15.
18. Alghisi GC, Ponsonnet L, Ruegg C. The integrin antagonist cilengitide activates alphaVbeta3, disrupts VE-cadherin localization at cell junctions and enhances permeability in endothelial cells. *PloS one*. 2009; 4:e4449. [PubMed: 19212436]
19. Reynolds AR, et al. Stimulation of tumor growth and angiogenesis by low concentrations of RGD-mimetic integrin inhibitors. *Nature medicine*. 2009; 15:392–400.
20. Zhu J, et al. Structure-guided design of a high-affinity platelet integrin alphaIIbbeta3 receptor antagonist that disrupts Mg(2)(+) binding to the MIDAS. *Science translational medicine*. 2012; 4:125ra132.
21. Bowditch RD, et al. Identification of a novel integrin binding site in fibronectin. Differential utilization by beta 3 integrins. *Journal of Biological Chemistry*. 1994; 269:10856–10863. [PubMed: 7511609]
22. Richards J, et al. Engineered fibronectin type III domain with a RGDWXE sequence binds with enhanced affinity and specificity to human alphavbeta3 integrin. *Journal of molecular biology*. 2003; 326:1475–1488. [PubMed: 12595259]
23. Scarborough RM. Development of eptifibatide. *American heart journal*. 1999; 138:1093–1104. [PubMed: 10577440]

24. Mould AP, et al. Integrin activation involves a conformational change in the alpha 1 helix of the beta subunit A-domain. *The Journal of biological chemistry*. 2002; 277:19800–19805. [PubMed: 11893752]
25. Kendall T, Mukai L, Jannuzi AL, Bunch TA. Identification of integrin beta subunit mutations that alter affinity for extracellular matrix ligand. *The Journal of biological chemistry*. 2011; 286:30981–30993. [PubMed: 21757698]
26. Takagi J, Petre BM, Walz T, Springer TA. Global conformational rearrangements in integrin extracellular domains in outside-in and inside-out signaling. *Cell*. 2002; 110:599–511. [PubMed: 12230977]
27. Adair BD, et al. Three-dimensional EM structure of the ectodomain of integrin {alpha}V{beta}3 in a complex with fibronectin. *The Journal of cell biology*. 2005; 168:1109–1118. [PubMed: 15795319]
28. Cluzel C, et al. The mechanisms and dynamics of (alpha)v(beta)3 integrin clustering in living cells. *The Journal of cell biology*. 2005; 171:383–392. [PubMed: 16247034]
29. Felding-Habermann B, et al. Involvement of tumor cell integrin alpha v beta 3 in hematogenous metastasis of human melanoma cells. *Clinical & experimental metastasis*. 2002; 19:427–436. [PubMed: 12198771]
30. Nagae M, et al. Crystal structure of alpha5beta1 integrin ectodomain: atomic details of the fibronectin receptor. *The Journal of cell biology*. 2012; 197:131–140. [PubMed: 22451694]
31. Sato Y, et al. An N-glycosylation site on the beta-propeller domain of the integrin alpha5 subunit plays key roles in both its function and site-specific modification by beta1,4-N-acetylglucosaminyltransferase III. *The Journal of biological chemistry*. 2009; 284:11873–11881. [PubMed: 19276077]
32. Roca-Cusachs P, Gauthier NC, Del Rio A, Sheetz MP. Clustering of alpha(5)beta(1) integrins determines adhesion strength whereas alpha(v)beta(3) and talin enable mechanotransduction. *Proceedings of the National Academy of Sciences of the United States of America*. 2009; 106:16245–16250. [PubMed: 19805288]
33. Xie C, et al. Structure of an integrin with an alphaI domain, complement receptor type 4. *The EMBO journal*. 2010; 29:666–679. [PubMed: 20033057]
34. Goodman SL, Picard M. Integrins as therapeutic targets. *Trends in pharmacological sciences*. 2012; 33:405–412. [PubMed: 22633092]

References

35. Cheresh DA. Human endothelial cells synthesize and express an Arg-Gly-Asp-directed adhesion receptor involved in attachment to fibrinogen and von Willebrand factor. *Proceedings of the National Academy of Sciences of the United States of America*. 1987; 84:6471–6475. [PubMed: 2442758]
36. Mehta RJ, et al. Transmembrane-truncated alphavbeta3 integrin retains high affinity for ligand binding: evidence for an 'inside-out' suppressor? *Biochem J*. 1998; 330(Pt 2):861–869. [PubMed: 9480902]
37. Cheng M, et al. Mutation of a Conserved Asparagine in the I-like Domain Promotes Constitutively Active Integrins {alpha}Lbeta2 and {alpha}Iibeta3. *The Journal of biological chemistry*. 2007; 282:18225–18232. [PubMed: 17468108]
38. Leahy DJ, Aukhil I, Erickson HP. 2.0 A crystal structure of a four-domain segment of human fibronectin encompassing the RGD loop and synergy region. *Cell*. 1996; 84:155–164. [PubMed: 8548820]
39. Mitjans F, et al. An anti-alpha v-integrin antibody that blocks integrin function inhibits the development of a human melanoma in nude mice. *J Cell Sci*. 1995; 108(Pt 8):2825–2838. [PubMed: 7593323]
40. Otwinowski, Z.; Minor, W. *Processing of X-ray diffraction data collected in oscillation mode*. Vol. Vol. 276. Academic Press; 1997.

41. Battye TG, Kontogiannis L, Johnson O, Powell HR, Leslie AG. iMOSFLM: a new graphical interface for diffraction-image processing with MOSFLM. *Acta Crystallogr D Biol Crystallogr*. 2011; 67:271–281. [PubMed: 21460445]
42. McCoy AJ, et al. Phaser crystallographic software. *Journal of applied crystallography*. 2007; 40:658–674. [PubMed: 19461840]
43. Adams PD, et al. PHENIX: a comprehensive Python-based system for macromolecular structure solution. *Acta Crystallogr D Biol Crystallogr*. 2010; 66:213–221. [PubMed: 20124702]
44. Emsley P, Cowtan K. Coot: model-building tools for molecular graphics. *Acta Crystallogr D Biol Crystallogr*. 2004; 60:2126–2132. [PubMed: 15572765]
45. Pettersen EF, et al. UCSF Chimera--a visualization system for exploratory research and analysis. *J Comput Chem*. 2004; 25:1605–1612. [PubMed: 15264254]




Figure 1. Binding properties of hFN10 and wtFN10 to α V β 3

Binding of fluoresceinated wtFN10 (a) and hFN10 (b) or LIBS mAbs (alone (c) or in presence of wtFN10 and hFN10 (d) to α V β 3⁺ cells. In (c), mAb-binding was assessed using K562- α V β 3 and M21 cells. MFI, mean fluorescence intensity. Histograms in a-d represent mean+SD, n=3 independent experiments. (e) Hydrodynamic analyses of unliganded α V β 3 and α V β 3-FN10 complexes in presence of Ca^{2+} , Ca^{2+} - Mg^{2+} or Mn^{2+} . Stokes radii (in nm) are shown in parentheses. AU: absorbance unit. (f-h) Mn^{2+} -induced spreading of K562- α V β 3 on wtFN10 (f), hFN10 (g) (mean+SD, n=3 independent experiments), or on full-length FN (f) (two independent experiments are shown). Spreading under all conditions was eliminated by mAb LM609 against α V β 3 (not shown). (g,h) Representative phase contrast images of K562- α V β 3 spreading on wtFN10 (g) and hFN10 (h). Bar = 20 μ m.




Figure 2. Structures of $\alpha V\beta 3$ bound to FN10

Ribbon diagrams of $\alpha V\beta 3$ head bound to wtFN10 (a) or hFN10 (b). Orientation of the integrin head in (a) and (b) is identical.

Mn^{2+} ions at LIMBS (gray), MIDAS (cyan) and ADMIDAS (magenta) are shown as spheres (also in Figs. 3a–b, 4c). (c) Orientation of bound FN10 relative to the superimposed βA domains (chain colors as in a, b). Mn^{2+} at MIDAS the ligand Asp (D1495) and the F- $\alpha 7$ loop are shown.




Figure 3. α V β 3-FN10 interfaces, conformational changes and structure validation

Ribbon diagrams showing key electrostatic and H-bond interactions and metal ion coordinations in α V β 3-wtFN10 (a) and α V β 3-hFN10 (b) structures. Chain colors are as in Fig. 2. Inset in b, enlarged view of σ A weighted $2Fo-Fc$ map contoured at 1.0σ of Trp1496 and Tyr122 side-chains in α V β 3-hFN10 complex. Inward movement (blue arrow) of Tyr122 (in light green) in wtFN10-bound β A would clash with Trp1496 side chain. (c) Left panel, β A domain from α V β 3-hFN10 (in pink) superimposed on that of α V β 3-wtFN10 (in light green) and on β A domain (in dark green) from unliganded α V β 3 (pdb 3ije) (right panel).

Blue arrow in left panel in (c) indicates direction of wtFN10-induced inward movement of α 1 helix (and ADMIDAS ion) towards MIDAS. Spheres representing the three metal ions bear the color of respective β A. The major tertiary change observed

in the F- α 7 loop of wtFN10-bound β A (c, left panel) was not translated into a one-turn displacement of α 7, possibly the result of crystal contacts when the complete ectodomain is used in crystallization. Except for ligand-occupancy and resulting changes in SDL loop, structures of unliganded- and hFN10-bound β A domains are identical (c, right panel) (LIMBS and MIDAS are not occupied by metal in unliganded β A). (d) Left panel, binding of fluoresceinated AP5 to M21 cells in absence (control) or presence of unlabeled wtFN10, hFN10 or hFN10W/S. Right panel, binding of fluoresceinated AP5 to α V β 3⁺ or α V β 3(Y122A)⁺ HEK293T in presence of unlabeled wt- or hFN10. Histograms represent mean \pm SD, n=3 independent experiments.




Figure 4. RGD-containing loop structures in wild type and modified FN10

(a) Superimposed R/KGD-containing loops of hFN10, eptifibatide (pdb id 2vdn) and barbourin (pdb id 1q7j, model 2). Residues R/KGDWN common to hFN10 and barbourin are labeled in black and the three flanking residues are in the respective loop color. (b) Superimposed structures of RGD-containing loops of α V β 3-hFN10, α V β 3-wtFN10, barbourin and α V β 3-hFN10/B. The position the Ca and C β of Trp1496 in the α V β 3-hFN10/B complex is as that in barbourin or eptifibatide. (c) Main ionic interactions at the α V β 3-hFN10/B interface involving the RGD-containing loop (in dark cyan). (d) Binding (mean \pm SD, n=3 independent experiments) of fluoresceinated AP5 mAb to M21 cells in absence (control) and presence of wtFN10, hFN10 or hFN10/B.

Table 1

Data collection and refinement statistics (molecular replacement)

	α V β 3-hFN10	α V β 3-wtFN10	α V β 3-hFN10/B
Data collection			
Space group	<i>P</i> 3221	<i>P</i> 3221	<i>P</i> 3221
Cell dimensions			
<i>a</i> , <i>b</i> , <i>c</i> (Å)	129.8, 129.8, 307.6	129.7, 129.7, 305.8	130.0, 130.0, 308.2
α , β , γ (°)	90, 90, 120	90, 90, 120	90, 90, 120
Resolution (Å)	50-3.1 (3.21-3.1)*	75.49-3.32 (3.5-3.32)	50-3.17 (3.28-3.17)
<i>R</i> _{sym}	7.9 (79.7)	10.9 (67.2)	10.4 (89.4)
<i>I</i> / σ <i>I</i>	27.1 (2.3)	13.9 (3.3)	12.6 (2.2)
Completeness (%)	99.9 (100)	88.0 (88.0)	99.7 (99.7)
Redundancy	6.1 (6.1)	6.2 (6.4)	5.3 (5.1)
Refinement			
Resolution (Å)	49.3-3.1	42.5-3.32	49.4-3.18
No. reflections	55,243	39,536	51,260
<i>R</i> _{work} / <i>R</i> _{free}	20.5/ 25.5	21.1/ 25.8	20.5/ 23.9
No. atoms			
Protein	12,794	12,922	13,000
Ligand/Ion			
FN10	690	694	65
Mn ²⁺	8	8	8
Water	9	2	5
<i>B</i> factors			
All atoms (Å ²)	116.7	102.8	75.8
Protein	114.2	98.5	75.7
Ligand/Ion			
FN10	163.2	181.8	83.7
Mn ²⁺	135.9	102.9	80.5
Water	95.2	67.7	54.8
r.m.s. deviations			
Bond lengths (Å)	0.004	0.003	0.005
Bond angles(°)	0.89	0.9	0.98

* Values in parenthesis are for highest-resolution shell. One crystal was used for each dataset.